Cipla Ltd

Cipla Expands into Paediatric Pharma with Inzpera Acquisition 💊

- Cipla acquires 100% stake in Inzpera Healthsciences, making it a wholly owned subsidiary.

- Inzpera specializes in paediatric pharmaceutical and wellness products.

- Enterprise value: ₹120 Cr; purchase consideration: ~₹110.65 Cr (cash deal).

- Expected completion within one month post-signing.

- Inzpera’s turnover: FY 2024-25 (₹26.75 Cr), FY 2023-24 (₹22.05 Cr), FY 2022-23 (₹20.76 Cr).

- Founded in 2016, operates in India; not a related-party transaction.